Advertisement


Ronald J. Buckanovich, MD, PhD, on Ovarian Cancer: Expert Perspective on the SOLO2 Trial

2017 ASCO Annual Meeting

Advertisement

Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on health-related quality of life with maintenance olaparib compared with placebo following chemotherapy in patients with germline BRCA-mutated platinum-sensitive relapsed serous ovarian cancer. (Abstract 5507)



Related Videos

Breast Cancer

Gunter von Minckwitz, MD, on HER2+ Breast Cancer: Results From the APHINITY Trial

Gunter von Minckwitz, MD, of the German Breast Group, discusses study findings on a randomized comparison of chemotherapy, trastuzumab, and placebo vs chemotherapy, trastuzumab, and pertuzumab as adjuvant therapy in patients with HER2-positive early breast cancer. (Abstract LBA500)

Head and Neck Cancer
Issues in Oncology

Maura L. Gillison, MD, PhD, on HPV and the Value of the Vaccine

Maura L. Gillison, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses her findings on the impact of prophylactic human papillomavirus vaccination on oral HPV infections among young adults in the United States. (Abstract 6003)

Symptom Management
Pain Management

Peter Hoskin, MD, on Spinal Compression: Results From the SCORAD III Trial

Peter Hoskin, MD, of Mount Vernon Cancer Centre, discusses study findings on single-dose radiotherapy compared with multifraction radiotherapy in patients with metastatic spinal canal compression. (Abstract LBA10004)

Solid Tumors

David M. Hyman, MD, on Larotrectinib in TRK Fusion Cancers: Trial Results

David M. Hyman, MD, of Memorial Sloan Kettering Cancer Center, discusses findings on the efficacy of larotrectinib, a selective tropomyosin receptor kinase inhibitor, in adult and pediatric cancers. (Abstract LBA2501)

Lung Cancer

Taofeek K. Owonikoko, MD, PhD, on SCLC: Results of the ECOG-ACRIN 2511 Trial

Taofeek K. Owonikoko, MD, PhD, of Emory University, discusses study findings on cisplatin and etoposide in combination with veliparib or placebo for extensive stage small cell lung cancer. (Abstract 8505)

Advertisement

Advertisement




Advertisement